Loading
Life sciences · Journal article
Oncology and Translational Medicine · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
B-cell lymphoma 6 (BCL6) is a transcriptional repressor essential for germinal center B-cell development, differentiation, and immune regulation. Aberrant overexpression or dysfunction of BCL6 drives lymphomagenesis, particularly in diffuse large B-cell lymphoma. Conventional small-molecule inhibitors have limitations such as poor selectivity and incomplete target inhibition. Proteolysis-targeting chimera (PROTAC) technology offers a strategy to overcome these limitations by facilitating the targeted degradation of BCL6. This review systematically outlines the progress of BCL6-targeted therapy from functional inhibition to protein degradation by analyzing preclinical and clinical data. PROTAC-based degraders exhibit better efficacy and specificity than traditional inhibitors, and early clinical trials support the therapeutic potential of BCL6 degradation. Although PROTACs have advanced BCL6-targeted treatment, several challenges remain. This review highlights current obstacles and future directions to guide rational therapeutic design.